NIH COVID-19 Panel Member Received Massive Windfall from Ivermectin Non-Recommendation
July 16th, 2021Good ‘ole grant swindling.
Via: TrialSiteNews:
About two months after the NIH meeting on ivermectin, the NIH announced the award NOT-TR-21–024; funding of ACTIV-6 to study the use of repurposed drugs in COVID-19. Duke University was the only institution in the country that met the criteria for the study, according to the NIH. Funding was thus distributed on a sole source basis. The “initial investment” in the trial was later announced to be $155 million. The principal investigator of the trial was not identified initially but, in a later announcement, was identified to be Susanna Naggie, who is also a member of the NIH COVID-19 Treatment Guidelines Panel.
The two positions Naggie holds clearly represent a conflict of interest. A positive recommendation on the use of the drug in COVID-19 would effectively end the clinical trial. The NIH award also raises the question of whether the prospect of the award played a role in the current recommendation on ivermectin.
The question was addressed to Naggie by email if she was the author of the NIH COVID-19 Treatment Guidelines recommendation on ivermectin. She has not responded to that question.
The review process of the NIH COVID-19 Treatment Guidelines is beyond suspicious. The NIH needs to provide the unredacted agenda to the January 6 meeting on ivermectin so that the identities of those responsible for the ivermectin recommendation are disclosed. Most importantly, we need to know if there was improper influence on the ivermectin recommendation.
